Impax Laboratories Retained Earnings Quarterly YoY Growth:
45.26% for March 31, 2013Impax Laboratories Historical Retained Earnings Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 45.26% |
| Dec. 31, 2012 | 17.64% |
| Sept. 30, 2012 | 24.73% |
| June 30, 2012 | 25.25% |
| March 31, 2012 | 24.14% |
| Dec. 31, 2011 | 26.07% |
| Sept. 30, 2011 | 23.47% |
| June 30, 2011 | 69.66% |
| March 31, 2011 | 100.4% |
| Dec. 31, 2010 | 30244% |
About Retained Earnings Growth
Retained Earnings Growth is the percent increase/decrease of a company's retained net income over time. A company can use retained earnings to maintain current operations, or to invest in new ventures. Generally speaking, retained earnings growth is accompanied by subsequent increases in sales and profitability.
If a company's retained earnings at the end of 2008 were $12 million, and by the end of 2009 the company's retained earnings increased to $15 million, the company experienced a retained earnings growth of 25%.
Learn More
IPXL Retained Earnings Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Endo Health Solutions | -43.54% |
| Actavis | -2.82% |
| Teva Pharmaceutical Industries | 6.70% |
IPXL Retained Earnings Quarterly YoY Growth Range, Past 5 Years
| Minimum | 17.64% | Dec 2012 |
| Maximum | 30244% | Dec 2010 |
| Average | 3060% |
IPXL News
Impax Labs (IPXL), Zogenix (ZGNX) Rise as FDA Won't Block Generic Opana (ENDP)
Street Insider May 10
Street Insider May 10
